Company Performance Metrics
James Wechuck: Co-Founder, Vice President, and Chief Scientific Officer- David Krisky: Co-Founder, President, and Chief Medical Officer
PeriphaGen is a biopharmaceutical company whose corporate objective is the development of first in class neuronal gene delivery products for neurologic disorders with significant unmet medical need. The intuitive way to treat conditions that directly affect neurons is to target treatment to the neurons themselves. PeriphaGen's first
indications of interest are neuropathic pain, neuropathy, and neuronal regeneration.
The PeriphaGen NEuronal Therapeutics (NET) platform based drug candidates have the ability to express therapeutic proteins directly and specifically in neurons for four to eight weeks after a simple intradermal application. NET products express natural gene products locally that block pain signaling, protect against neuronal damage, or promote neuronal regeneration without systemic side effects.
